Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells

[1]  V. Jordan,et al.  Tamoxifen to raloxifene and beyond. , 2001, Seminars in oncology.

[2]  L. Ford,et al.  From Adjuvant Therapy to Breast Cancer Prevention: BCPT and STAR , 2001, The breast journal.

[3]  T. Scanlan,et al.  Unique Protein Determinants of the Subtype-selective Ligand Responses of the Estrogen Receptors (ERα and ERβ) at AP-1 Sites* , 2001, The Journal of Biological Chemistry.

[4]  B. Vastag.  Breast cancer prevention study aims to overcome drug bias. , 2001, JAMA.

[5]  D. Agard,et al.  Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  B. Katzenellenbogen,et al.  The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. , 1999, Molecular endocrinology.

[7]  P. Carthew,et al.  Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse. , 1999, Toxicology and applied pharmacology.

[8]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[9]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[10]  A. Giuliano,et al.  Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF‐7 human breast cancer cells , 1998, International journal of cancer.

[11]  S. Mader,et al.  Estrogen Response Elements Can Mediate Agonist Activity of Anti-estrogens in Human Endometrial Ishikawa Cells* , 1998, The Journal of Biological Chemistry.

[12]  V. Jordan,et al.  Basic guide to the mechanisms of antiestrogen action. , 1998, Pharmacological reviews.

[13]  C. D. Jones,et al.  Molecular determinants of tissue selectivity in estrogen receptor modulators. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[15]  J. Simard,et al.  Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. , 1997, Cancer research.

[16]  S. Kato,et al.  Rapid activation of MAP kinase by estrogen in the bone cell line. , 1997, Biochemical and biophysical research communications.

[17]  R. Gopalakrishna,et al.  Tamoxifen Modulates Protein Kinase C via Oxidative Stress in Estrogen Receptor-negative Breast Cancer Cells* , 1996, The Journal of Biological Chemistry.

[18]  H. Bryant,et al.  Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  P. Bontempo,et al.  Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.

[20]  B. Katzenellenbogen,et al.  Antiestrogens: Mechanisms and actions in target cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  P. Webb,et al.  Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.

[22]  John H. White,et al.  A Simple and Sensitive High–Throughput Assay for Steroid Agonists and Antagonists , 1994, Bio/Technology.

[23]  Y. Yamasaki,et al.  Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. , 1994, The Journal of biological chemistry.

[24]  T. Bourne,et al.  Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial , 1994, The Lancet.

[25]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[26]  J. Willem,et al.  Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.

[27]  D. Williams,et al.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.

[28]  S. Mader,et al.  A steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Powles.  The case for clinical trials of tamoxifen for prevention of breast cancer , 1992, The Lancet.

[30]  J. Croxtall,et al.  The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). , 1991, Journal of molecular endocrinology.

[31]  P. Chambon,et al.  Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex , 1990, Cell.

[32]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[33]  V. Jordan,et al.  Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. , 1990, Cancer research.

[34]  P Chambon,et al.  Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.

[35]  H. Kuramoto,et al.  Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). , 1989, Cancer research.

[36]  S. Robinson,et al.  Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.

[37]  V. Jordan,et al.  Antiestrogen therapy for breast cancer: current strategies and future prospects. , 1988, Cancer treatment and research.